

NCI

National
Clinical
Trials
Network

EA3231

ECOG-ACRIN
cancer research group

For Patients with Thyroid Cancer

EA3231 Available Through ECOG-ACRIN Cancer Research Group

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

**Please Enroll
Your Eligible
Patients!**

Patient Population

See Section 3 for complete eligibility details

- ≥ 18 years of age, ECOG PS 0-2, adequate lab values
- Must have differentiated thyroid cancer (DTC) with BRAF V600E mutation as determined by local testing, including the papillary/follicular thyroid carcinoma subtypes per protocol (note: results of a previous biopsy will be accepted)
- Must have been previously treated with or deemed ineligible for treatment with Iodine-131 for DTC and must be receiving thyroxine suppression therapy
- Must have had prior treatment with at least one VEGFR-targeting TKI agent for DTC: lenvatinib or sorafenib (note: up to 2 prior VEGFR-targeting TKI agents are allowed, including but not limited to lenvatinib and sorafenib)
- Must have measurable disease (RECIST 1.1) on chest CT/abdominal/pelvis CT/MRI performed within 4 weeks prior to randomization
- Must have radiographic progression (RECIST 1.1) over any time interval on or after most recent prior systemic treatment
- Patient must not have the cardiovascular and thromboembolic disorders/medical conditions per protocol
- Must not have any clinically significant hematemesis/haemoptysis of > 2-5mL of red blood/history of other significant bleeding within 3 months of randomization
- Must not have any cavitating pulmonary lesions/lesions invading major pulmonary blood vessels
- Must not be on any concomitant anticoagulation with oral anticoagulants/platelet inhibitors (exceptions per protocol)
- Must not have any GI disorders associated with a high risk of perforation/fistula formation (described per protocol)
- Must not have any lesions with ≥ 2cm growth within 3 months or ≥ 1.5cm growth within 2 months of randomization, and must not have documented anaplastic histology at or following cancer recurrence
- No prior treatment with cabozantinib/any prior BRAF-targeted therapy for thyroid cancer

Treatment Plan

See Section 5 for complete treatment details

1 cycle = 28 days

Arm A:

- Dabrafenib 150mg PO BID
- Trametinib 2mg PO QD
- Continue treatment until progression/unacceptable toxicity

Arm B:

- Cabozantinib 60mg tablet PO QD (do not substitute cabozantinib tablets with cabozantinib capsules)
- Continue treatment until progression/unacceptable toxicity

Crossover:

- Patients will be allowed to crossover to the other treatment arm at the time of RECIST progression
 - ◇ Patients are not allowed to crossover for toxicity reasons
- Patients who do crossover should continue treatment until second RECIST progression/unacceptable toxicity

Note:

- Dabrafenib, trametinib, and cabozantinib to be administered on an empty stomach; swallowed whole
- If a dose of dabrafenib is missed, it should not be taken if it is within 6 hours of the next scheduled dose (take the next dose at the regular time)
- If a dose of trametinib is missed, the dose can be taken if it is more than 12 hours until the next scheduled dose (take the trametinib dose at the same time each day with either the morning or evening dose of dabrafenib)
- If a dose of cabozantinib is missed, it may be taken as long as it is within 12 hours of the usual scheduled dose
- Patients will be asked to maintain a Medication Calendar

Study Chair:
Lova Sun, MD

Study Co-Chair:
Nabil F. Saba, MD

Patient Enrollment (Oncology Patient Enrollment Network [OPEN])



<https://open.ctsu.org/open>



1-888-823-5923

Protocol Information (ECOG-ACRIN Operations – Boston)




<http://ecog-acrin.org> (Member Login)



1-857-504-2900

EA3231

Schema



N=240
Randomization 1:1